摘要
移植后淋巴增殖性疾病(PTLD)是器官移植后的严重且可能致命的并发症,EB病毒感染在发病机制中起关键作用,发病与移植前EB病毒血清学状态及移植类型、免疫抑制强度、移植年龄等因素密切相关。EBV检测在疾病诊断中至关重要。治疗应首先减低免疫抑制,多数病例还需要采用抗CD20单抗和(或)化疗等措施。本文就器官移植后EB病毒相关PTLD的研究现状作一综述。
Post-transplant lymphoproliferative disorder （PTLD） is recognized as a serious and potentially lethal complication of solid organ transplantation.Epstein-barr virus （EBV） is known to play a major role in the development of PTLD.The incidence of PTLD is varying according to pretransplant EBV serostatus,the type of graft,intensity of immunosuppression and age of the recipient.EBV related tests are of essential importance in the diagnosis of EBV associated PTLD.Reduction of immunosuppression is the initial approach to PTLD management.Most patients require further treatment,such as anti-CD20 monoclonal antibody and/or chemotherapy.This review concentrates on these recent advances in this field.
出处
《西部医学》
2014年第10期1412-1414,F0003,共4页
Medical Journal of West China
基金
四川省科技厅支撑计划项目(2010FZ0046)
